Background: Formulation of neuraminidase (NA) within influenza vaccines is gaining
| INTRODUC TI ON
Neuraminidase is the second most abundant glycoprotein on the influenza virus surface (17% of the overall surface) after HA and it is usually expressed at a ratio 1:4 (40-50 NA and 160-200 HA spikes), 1 with exceptions. [2] [3] [4] NA has multiple roles: (a) allow the release of newly formed virions from the surface of the infected cell, leading to viral spread, (b) enhance influenza infection by acting on glycoconjugates expressed at the cell surface, 5 and (c) form complexes with sialic acids on the host cell surface, 6, 7 particularly for H3N2
viruses. 8 Several studies have confirmed that both inactivated and live attenuated vaccines have the capacity to induce NA-specific antibodies. 9, 10 NA inhibiting antibodies are associated with resistance against influenza, 11, 12 reduced severity and duration of disease.
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Several different assays have been used to evaluate the antibody response to NA. The traditional NA inhibition (NI) assay determines the extent of antibody-mediated interference with viral enzyme activity based on the measurement of sialic acid that is released from a glycosylated substrate. 14 An assay that measures NA activity based on accessibility of galactose, the penultimate sugar of many complex carbohydrates, to peanut agglutinin, offers advantages in that it does not use hazardous chemicals and has higher throughput. This enzyme-linked lectin assay (ELLA) developed by Lambré et al 15 and
successively adapted and optimized, 10, 16, 17 measures sialidase activity of NA by detecting the terminal galactose that becomes exposed after sialic acid cleavage. A study conducted by Eichelberger et al 18 that employed the protocol published by Couzens et al 17 showed
that the ELLA is robust and sensitive although improvements can be made to further standardization of the method.
Measuring the NI antibody only is possible if HA-specific antibodies are unable to bind to the virus. This is usually accomplished by using reassortant viruses that have a mismatched avian HA, although it should be kept in mind that antibodies against conserved HA epitopes 19 can still occur. The production of reassortant influenza viruses, beyond the intrinsic difficulty of optimizing the process, limits many laboratories from using these as a source of antigen since genetically modified organisms require additional biosafety containment and in some countries a permit from the Department of Agriculture. This is due to the HA gene, that is usually derived from an avian source. Carolyn Nicolson, NIBSC), as previously described. [22] [23] [24] [25] The H11 plasmid was added to improve NA stability and increase the PV release and production as previously described 26 and confirmed for this assay. 22, 25 Briefly, 1 µg of HA, 1 µg of NA, and 1.5 µg pNLLuc4.3 plasmids were transfected into HEK293T/17 cell lines using Endofectin™ Lenti (3 µL/ µg). Medium was replenished 24 hours after transfection. The NA activity of each PV was titrated in ELLA as reported previously. 
| Serum samples
Two different panels of 40 (S1.1-S1.40) and 34 (S2.1-S2.34) human sera were tested against N1 and N2 NAs, respectively. Information about gender, age, and vaccination status was not provided.
| HA assay
HA assays were performed to confirm the inability of Triton X-100 treated virus to agglutinate RBCs. The protocol was described elsewhere (WHO 2011, Manual for the laboratory diagnosis and virological surveillance of influenza).
| ELLA assay
ELLA assays were performed as previously described, 17 IC 50 values were automatically generated using Graph Pad Prism 5® software.
| Statistical evaluation
Every serum sample was tested in duplicate and evaluated by both 50% end point titer and IC 50 outcomes. 22 The percent inhibition of enzyme activity is calculated as follows: background optical density (OD) is subtracted from the virus control (maximum NA activity, no serum added) and sample ODs. The 50% end point titer is calculated as the highest serum dilution that resulted in at least 50% inhibition of the maximum NA activity. IC 50 values were generated through a non-linear regression curve fit using GraphPad Prism 5®, as described elsewhere.
25
The geometric mean titer (GMT) of end point titers was reported as Log 2 and compared by simple non-linear regression curve fit, and r 2 (coefficient of determination), a measure of strength of the relation between two variables. 27 To investigate the relationship between the errors in measurement and the true values, the mean difference (d) and the standard deviations of the differences (s) were calculated. 27 The Spearman rank calculation was also used to compare the outputs, as reported elsewhere.
28
In addition, Log 2 of IC 50 titers determined from inhibitory curves were also compared. Coefficient of determination (r 2 ), the mean difference (d), and the standard deviation of the differences (s) were evaluated by Bland and Altman and Spearman rank analyses. 
| RE SULTS

| Preparation of Triton X-100-treated antigens
| H6N1, H1N1-Tx, and H11N1 PV sources of antigen show comparable NI antibody titers
H6N1 reassortant virus, N1-Tx, and H11N1 PV were titrated in ELLA to determine the appropriate amount of antigen to use in each assay.
The amount of antigen added to each assay was 90% of the maximum OD for each source of antigen. ELLA assays were performed to measure NI antibody titers of 40 sera against each N1 antigen, (Figures 1 and 2 ). values, obtained using Graph Pad Prism 5®, were collected and analyzed.
The inhibition curves were obtained by performing non-linear regression from every serum run in duplicate (GMT is shown) against each N1 source of antigen (Figures 1 and 2 ).
N1-Tx end point titers were similar to titers using H11N1 PV as antigen in 90% of all the cases (36/40) of which 17/36 were identical (42.5%). There was a greater than 2-fold difference in only 4 cases.
NI titers measured in assays using H11N1 PV and H6N1 reassortant viruses were similar in 90% of all the cases (36/40) of which 14 sera had the same titer (35% As expected, the Bland-Altman analyses performed with 50% end point and IC 50 titers are similar (Figures 4 and 6 ). The BlandAltman analysis of IC 50 titer differences showed a trend for larger differences measured by the three assays at low titers ( Figure 6 ). This is evident from the titers reported in Table 1; sera 19, 22, and 23 all have low or unmeasurable (<10) titers using PV and N1-Tx antigens, but a reasonable titer measured in assays using H6N1 as antigen.
| NA inhibition antibody titers measured in ELLA with H6N2 and H11N2 PV sources of antigen are similar
Since an N2-Tx virus was not available, NI antibody titers measured by ELLA using only H6N2 and H11N2 PV antigens were compared (Figures 7 and 8 ).
The protocol used for each antigen was the same, with the exception of HRPO concentration which was used at a higher TA B L E 1 ELLA assay outcomes (S1.1-S1.40) from the 3 different sources of antigen for N1 NA. Individual NI titers and GMTs of the results are shown there was excellent consistency in both high and low titer replicate measurements within each assay and between assays using different antigens. The end point titers measured in both assays are shown in Table 2 . There are no significant differences at high or low titers respectively. Interestingly the N2-specific GMTs measured using these different antigens are closer than N1-specific GMTs measured in ELLA using H11N1 PV and H6N1 antigens. Nevertheless, the higher variety in titers within the N2 panel has probably determined a lesser consistency between data, affecting the coefficient of correlation.
As for N1 titers, the Bland-Altman analysis on N2 titers show small differences in titers measured using the different antigens when either end point titers or IC 50 titers were plotted ( Figure 10 ).
Only one serum (10) was greater than the higher limit of agreement, when end point titers measured by H11N2 PV were compared with H6N2 titers. In fact, this is the only case in which the titer measured in an assay using H11N2 PV antigen is 2-fold higher than the titer measured with H6N2 as antigen. In addition, sera 23 and 29 were greater than the higher limit of agreement, when differences in IC 50 titers from assays using H11N2 PV and H6N1 antigens were The correlations of titers were also evaluated by Spearman rank analysis for both N1 and N2 assays. As shown in Table 3 , all the results showed good correlation when either IC 50 or end point titers were evaluated.
In conclusion, measurement of NI antibody titers against N1 and N2 antigens by ELLA demonstrate comparable results using PV or Triton X-100-disrupted virions and the gold-standard H6 reassortant viruses.
F I G U R E 7 Inhibition curves showing the ability of sera to inhibit the sialidase activity across the plate. Sera from 1 to 20 (corresponding to plates 1-5) were tested in duplicate (GMTs here reported) against H6N2 reassortant virus (left column) and H11N2 PV (right column). Y axes represent the percentage of inhibition while X axes report the Log2 of the dilution. The prefix "2." in front of every serum number is omitted to improve the readability of the legend
| D ISCUSS I ON
This is the first study that compares NI antibody titers from assays employing three different sources of NA. The study included panels of sera tested against N1 and N2 antigens in the form of whole influ- (Table 3) , suggesting the suitability of performing ELLA with any of these antigen sources. As observed from the Bland-Altman analyses, titers measured against N2 antigens
were in better agreement than N1 titers measured using H6N1
and H11N1 PV antigens. This suggests the N1 assays did not have equivalent sensitivity. This may be a result of using different absolute amounts of NA in each assay or the impact of extrinsic factors on assay performance. Further studies are needed to examine the reason for higher titers being measured using H6N1 as the F I G U R E 8 Inhibition curves showing the ability of sera to inhibit the sialidase activity across the plate. Sera from 21 to 34 (corresponding to plates 6-9) were tested in duplicate (GMTs here reported) against H6N2 reassortant virus (left column) and H11N2 PV (right column). Y axes represent the percent inhibition while X axes report the Log2 of the serum dilution. The prefix "2." in front of every serum number is omitted to improve the readability of the legends 
